Bleeding is a leading cause of death in patients undergoing coumarin therapy (oral vitamin K) to inhibit blood clot formation. Assessing optimal drug dosage rapidly and cost effectively is thus a critical issue that needs resolving in order to improve patient safety.
Further information: cordis.europa.eu